<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800926</url>
  </required_header>
  <id_info>
    <org_study_id>18-002369</org_study_id>
    <nct_id>NCT04800926</nct_id>
  </id_info>
  <brief_title>Xavier Electromyographic Wheelchair Control for Limited Mobility Patients</brief_title>
  <official_title>Xavier Electromyographic Wheelchair Control for Limited Mobility Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Central Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the functional mobility and self-reported satisfaction&#xD;
      with the Xavier electromyography hands-free wheelchair control system in comparison with a&#xD;
      standard joystick.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2019</start_date>
  <completion_date type="Actual">October 30, 2019</completion_date>
  <primary_completion_date type="Actual">October 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wheelchair Skills Test (WST)</measure>
    <time_frame>approximately 3 days</time_frame>
    <description>Questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drive test</measure>
    <time_frame>approximately 3 days</time_frame>
    <description>Driving around cones in a controlled environment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Xavier wheelchair controller</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surface electromyography control of wheelchair</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xavier wheelchair controller</intervention_name>
    <description>Controlling a wheelchair using the Xavier surface EMG system</description>
    <arm_group_label>Xavier wheelchair controller</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ALS diagnosis by revised el Escorial criteria (definite, probable or probable&#xD;
             laboratory supported)&#xD;
&#xD;
          -  Age 18-89&#xD;
&#xD;
          -  Limited mobility with use of motorized wheelchair at screening-time&#xD;
&#xD;
          -  Impairment of hand function limiting the use of a standard joystick control&#xD;
&#xD;
          -  Caregiver willing to assist with transfers into wheelchair and application of&#xD;
             controllers&#xD;
&#xD;
          -  Ability to attend study visits with a motorized wheelchair&#xD;
&#xD;
          -  Ability to communicate and answer patient reported outcome measure questions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cognitive impairment prohibiting safe independent mobility as defined by an&#xD;
             ALS-Cognitive Behavioral Screen (ALS-CBS) score of &lt;10 or the opinion of the&#xD;
             investigator&#xD;
&#xD;
          -  A sensory impairment prohibiting safe independent mobility in the opinion of the&#xD;
             investigator&#xD;
&#xD;
          -  Allergy to adhesives or electrode gels (required for EMG electrodes)&#xD;
&#xD;
          -  Skin breakdown over the temporalis muscle that would predispose to further breakdown&#xD;
             and/or infection with electrodes&#xD;
&#xD;
          -  Severe loss of facial muscle functionality or control that would preclude EMG&#xD;
             electrode efficacy&#xD;
&#xD;
          -  Subjects who do not have the capacity to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bjorn Oskarsson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 14, 2021</last_update_submitted>
  <last_update_submitted_qc>March 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Bjorn E. Oskarsson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

